Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Scheen

Showing results (301-310 of 595) with videos related to

Pageof 60
Sort By:
Revue Medicale De Liege|July 23, 2005
[Insulin therapy in type 2 diabetes]J C Philips, A J Scheen
Drug Safety|January 1, 1995
Antihyperglycaemic agents. Drug interactions of clinical importanceA J Scheen, P J Lefèbvre
Diabetes Research and Clinical Practice|May 15, 1989
Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureasA J Scheen, P J Lefèbvre
Revue Medicale De Liege|January 26, 2008
[A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge]J M Krzesinski, A J Scheen
Acta Gastro-Enterologica Belgica|August 10, 2010
Management of metabolic syndrome and associated cardiovascular risk factorsJ De Flines, A J Scheen
Revue Medicale De Liege|December 30, 2004
[The drug of the month: Olmesartan medoxomil]J M Krzesinski, A J Scheen
Diabetic Medicine : a Journal of the British Diabetic Association|December 30, 1998
The postprandial state and risk of cardiovascular diseaseP J Lefèbvre, A J Scheen
Bulletin Et Memoires De L'Academie Royale De Medecine De Belgique|January 1, 1996
[Non-insulin-dependent diabetes: from physiopathology to treatment]A J Scheen, P J Lefebvre
Acta Chirurgica Belgica|July 31, 1999
Medical aspects of obesityA J Scheen, F H Luyckx
Diabetes Care|September 10, 1999
Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetesA J Scheen, P J Lefèbvre
Pageof 60

Showing results (301-310 of 595) with videos related to

Sort By:
Pageof 60
Revue Medicale De Liege|July 23, 2005
[Insulin therapy in type 2 diabetes]J C Philips, A J Scheen
Drug Safety|January 1, 1995
Antihyperglycaemic agents. Drug interactions of clinical importanceA J Scheen, P J Lefèbvre
Diabetes Research and Clinical Practice|May 15, 1989
Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureasA J Scheen, P J Lefèbvre
Revue Medicale De Liege|January 26, 2008
[A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge]J M Krzesinski, A J Scheen
Acta Gastro-Enterologica Belgica|August 10, 2010
Management of metabolic syndrome and associated cardiovascular risk factorsJ De Flines, A J Scheen
Revue Medicale De Liege|December 30, 2004
[The drug of the month: Olmesartan medoxomil]J M Krzesinski, A J Scheen
Diabetic Medicine : a Journal of the British Diabetic Association|December 30, 1998
The postprandial state and risk of cardiovascular diseaseP J Lefèbvre, A J Scheen
Bulletin Et Memoires De L'Academie Royale De Medecine De Belgique|January 1, 1996
[Non-insulin-dependent diabetes: from physiopathology to treatment]A J Scheen, P J Lefebvre
Acta Chirurgica Belgica|July 31, 1999
Medical aspects of obesityA J Scheen, F H Luyckx
Diabetes Care|September 10, 1999
Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetesA J Scheen, P J Lefèbvre
Pageof 60